News & Updates
Filter by Specialty:

MIRV treatment effects sustained in PROC despite dose modifications
02 Aug 2024
byAudrey Abella
In a post hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial, mirvetuximab soravtansine (MIRV) continues to demonstrate clinically meaningful improvements in survival and objective response rate (ORR) in women with platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha (FRα) expression who necessitated dose modifications.
MIRV treatment effects sustained in PROC despite dose modifications
02 Aug 2024
Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer
31 Jul 2024
Treatment with antiplatelet medications and age are some of the factors associated with the occurrence of radiation proctitis in patients with locally advanced cervical cancer treated by chemoradiation, a recent study has shown.